CRDF (Cardiff Oncology) Cash from Discontinued Operating Activities : $0.00 Mil (TTM As of Sep. 2024)

View and export this data going back to 1997. Start your Free Trial

What is Cardiff Oncology Cash from Discontinued Operating Activities?

Cash from Discontinued Operating Activities is net cash from all of the entity's discontinued operating activities.

Cardiff Oncology's Cash from Discontinued Operating Activities for the three months ended in Sep. 2024 was $0.00 Mil. It means Cardiff Oncology received $0.00 Mil from discontinued investing activities. Cardiff Oncology's Cash from Discontinued Operating Activities for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00 Mil.

Cardiff Oncology Cash from Discontinued Operating Activities Historical Data

The historical data trend for Cardiff Oncology's Cash from Discontinued Operating Activities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardiff Oncology Cash from Discontinued Operating Activities Chart

Cardiff Oncology Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash from Discontinued Operating Activities

Get a 7-Day Free Trial

Cardiff Oncology Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Cash from Discontinued Operating Activities	Get a 7-Day Free Trial															-	-	-	-	-

Cardiff Oncology Cash from Discontinued Operating Activities Calculation

Cash from Discontinued Operating Activities is net cash from all of the entity's discontinued operating activities.

Cash from Discontinued Operating Activities for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Cardiff Oncology Cash from Discontinued Operating Activities Related Terms

Thank you for viewing the detailed overview of Cardiff Oncology's Cash from Discontinued Operating Activities provided by GuruFocus.com. Please click on the following links to see related term pages.

Cardiff Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cardiff Oncology Inc (NAS:CRDF) » Definitions » Cash from Discontinued Operating Activities

Comparable Companies

Traded in Other Exchanges

XE7C:Germany

Address

11055 Flintkote Avenue, San Diego, CA, USA, 92121

Website

https://www.cardiffoncology.com

Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").

Executives

Gary W Pace	director	C/O RESMED INC, 14040 DANIELSON STREET, POWAY CA 92064-6857
Fairooz Kabbinavar	officer: Chief Medical Officer	C/O TOCAGEN INC., 4242 CAMPUS POINT COURT, STE. 500, SAN DIEGO CA 92121
Mark Erlander	officer: Chief Scientific Officer	C/O TROVAGENE, INC., 11055 FLINTKOTE AVENUE, SUITE A, SAN DIEGO CA 92121
Lale White	director	310 GODDARD, SUITE 150, IRVINE CA 92618
James O Armitage	director	C/O TESARO, INC., 1000 WINTER ST., SUITE 3300, WALTHAM MA 02451
James E. Levine	officer: Chief Financial Officer	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Renee P Tannenbaum	director	9220 KIRBY DRIVE, SUITE 500, HOUSTON TX 77054
Tod Smeal	officer: Chief Scientific Officer	11055 FLINTKOTE AVENUE, SA DIEGO CA 92121
Katherine L Ruffner	officer: Chief Medical Officer	11055 FLINTKOTE AVENUE, SAN DIEGO CA 92121
Mani Mohindru	director	C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, STAMFORD CT 06902
Rodney S Markin	director	C/O UNIVERSITY OF NEBR MEDICAL CENTER, 983135 NEBRASKA MEDICAL CENTER, OMAHA NE 68198-3135
Gary S Jacob	director
Vicki Kelemen	officer: Exec. VP and COO	11055 FLINTKOTE AVENUE, SAN DIEGO CA 92121
John P Brancaccio	director	C/O TAMIR BIOTECHNOLOGY, INC., 11 DEER PARK DRIVE, SUITE 204, MONMOUTH JUNCTION NJ 08852
Rajeev M. Shah	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116